Evofem Biosciences, Inc. (EVFM): Price and Financial Metrics
EVFM Price/Volume Stats
|Current price||$0.07||52-week high||$10.63|
|Prev. close||$0.07||52-week low||$0.06|
|Day high||$0.07||Avg. volume||94,873|
|50-day MA||$0.09||Dividend yield||N/A|
|200-day MA||$1.17||Market Cap||868.00K|
EVFM Stock Price Chart Interactive Chart >
Evofem Biosciences, Inc. (EVFM) Company Bio
Evofem Biosciences, formerly Neothetics, develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. Its lead candidate is Amphora, a non-hormonal, surfactant-free bioadhesive vaginal gel designed for on-demand use as needed or desired by a woman. This investigational new drug is being developed as an on-demand, non-hormonal vaginal contraceptive and for the prevention of certain sexually transmitted infections (STIs). Data from a confirmatory Phase 3 clinical trial of Amphora for the prevention of pregnancy are expected in late 2018/early 2019. A Phase 2b/3 clinical trial of Amphora for the prevention of urogenital chlamydia and gonorrhea in women is also underway. Amphora received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention of urogenital chlamydia in women, and is designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for the prevention of urogenital gonorrhea infection in women. The Company's second multipurpose prevention technology (MPT) vaginal gel candidate has QIDP designation for the reduction of reoccurrence of bacterial vaginosis. These designations may enable Evofem Biosciences to more rapidly evaluate and make these drugs available to women at risk of these infections.
EVFM Latest News Stream
|Loading, please wait...|
EVFM Latest Social Stream
View Full EVFM Social Stream
Latest EVFM News From Around the Web
Below are the latest news stories about EVOFEM BIOSCIENCES INC that investors may wish to consider to help them evaluate EVFM as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Evofem Biosciences (OtherEVFM), Greenwich LifeSciences (GLSI) and Chinook Therapeutics (KDNY)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evofem Biosciences (EVFM – Research Report), Greenwich LifeSciences (GLSI – Research Report) and Chinook Therapeutics (KDNY – Research Report) with bullish sentiments. Evofem Biosciences (EVFM) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Evofem Biosciences, with a price target of $4.00. The company's shares closed last Friday at $0.41, close to its 52-week low of $0.28. According to TipRanks.
Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences.
Evofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and improved loss from operations by 16% to $(24) million. The U.S. government clarified that it would enforce federal law requiring group health plans and health insurance issuers to cover contraception at no cost to participants. In June, Evofem announced an agree
Evofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance.
EVFM Price Returns